Linaprazan glurate for treating gastroesophageal reflux disease (gerd)
AssigneeCinclus Pharma Holding AB (Publ)
InventorsKjell Andersson, Peter Unge
Life of this patent
Estimating the term…
Abstract
The invention relates to linaprazan glurate, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a gastrointestinal inflammatory or a gastric acid related disease, such as (erosive) gastroesophageal reflux disease. The treatment involves oral administration of linaprazan glurate, or a pharmaceutically acceptable salt thereof, to a patient in an amount of from about (25) to about (100) mg once or twice daily.
Claims26
A method of treating or preventing a gastrointestinal inflammatory or a gastric acid related disease, comprising administering linaprazan glurate, or a pharmaceutically acceptable salt thereof, orally to a subject in an amount of from about 25 to about 100 mg twice daily.
6-7. (canceled)
A method of treating or preventing a gastrointestinal inflammatory or a gastric acid related disease, comprising administering linaprazan glurate, or a pharmaceutically acceptable salt thereof, orally, to a subject in an amount of from about 25 to about 100 mg twice daily, wherein following such oral administration the subject exhibits a minimum plasma concentration (Cmin) of linaprazan of at least 240 nmol/L.
Dependencies are inferred from the claim text.